Current service
A clinic removes a small number of hair follicles and a specialist facility cryopreserves tissue or cells. The rationale is that younger follicular material may be useful if compatible cell therapies become available later.
HairClone currently markets follicle banking through a clinical network. Banking itself is not hair cloning and does not add hairs to the scalp.
The central uncertainty
Stored follicles may provide starting material, but the eventual therapy, processing requirements, regulatory route, price and location are not guaranteed. Storage also creates continuing questions about fees, facility continuity, transfer rights and what happens if the provider changes ownership or closes.
Contract and consent considerations
Prospective customers should establish what is stored, who owns the material, how viability is monitored, whether samples can be transferred, which annual fees apply, what happens after missed payments and whether any future treatment cost is included. These terms should be confirmed in the contract and consent documents.